ROBOSENSE
19.5.2023 13:01:28 CEST | Business Wire | Press release
RoboSense, a world-leading provider of smart LiDAR sensor systems, today announced it is now connected to the NVIDIA Omniverse ecosystem, using the development platform based on Universal Scene Description (USD) to accelerate the development, testing, and validation of its sensor technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005153/en/
RoboSense Joins NVIDIA Omniverse Ecosystem RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. (Graphic: Business Wire)
RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. With this integration, autonomous vehicle developers can directly access state-of-the-art LiDAR for development and testing. (Video: RoboSense LiDAR Model in NVIDIA DRIVE Sim)
DRIVE Sim is a reference application built on NVIDIA Omniverse, the connecting fabric between software ecosystems. It combines NVIDIA’s core technologies to deliver digital twin environments for developing and testing autonomous driving systems. With DRIVE Sim, developers can perform diverse and repeatable testing scenarios at a large scale, accelerating development and reducing cost.
As part of the Omniverse ecosystem, RoboSense will use the simulation platform to test and validate its new LiDAR systems - as well as provide ADAS developers access to highly accurate simulation models.
RoboSense's M-Series LiDAR is the world's first second-generation smart solid-state LiDAR to achieve mass production for automotive applications. It is currently the LiDAR with the most designated partnerships worldwide and has been implemented in a variety of vehicle models including the GAC Aion LX Plus, GAC Aion Hyper GT, SAIC IM LS7, SAIC IM L7, Lotus Eletre, XPeng G9, XPeng P7i, Great Wall WEY Mocha DHT-PHEV, Great Wall Motor WEY DHT-PHEV, and Chery Exeed STERRA ES, STERRA ET.
The M-Series LiDAR features a revolutionary two-dimensional MEMS scanning architecture, with unique “GAZE” function that can dynamically switch scanning modes and change scanning patterns based on the scenario, improving vehicle perception in complex environments. Based on RoboSense's leading patented technology, the M-Series LiDAR delivers point-cloud with outstanding quality, helping to address corner cases in autonomous driving perception.
By joining the NVIDIA Omniverse ecosystem, RoboSense enables developers to create complex road environments with high physical accuracy using its LiDAR model on the DRIVE Sim platform. The M series LiDAR model offers the flexibility to simulate its performance in beam control, custom scan patterns, and resolutions, which can then be used to generate synthetic datasets for training and validation of autonomous driving solutions.
Mark Qiu, co-founder and executive president of RoboSense, said, “The global automotive industry is undergoing a massive transformation, with ADAS and LiDAR markets continuing to gain traction. Leveraging the NVIDIA Omniverse ecosystem, RoboSense LiDAR technology and industry experience can be applied in a wider field, providing strong support for the development and verification of autonomous vehicles. RoboSense will work with NVIDIA to fully leverage the advantages of LiDAR technology, continuously improve the perception capabilities of autonomous vehicles, and achieve more efficient, safer, and smarter autonomous driving applications. We are committed to promoting the development of the global automotive and autonomous driving industries.”
Zvi Greenstein, a general manager at NVIDIA, said, “NVIDIA Omniverse is an open platform that includes leading LiDAR models from manufacturers worldwide. RoboSense's outstanding technical strength and customer base help strengthen our ecosystem and will accelerate the development and validation of autonomous vehicles while bringing more flexibility to developers.”
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom